EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin

Xin Shi, Wei Jun Wang, Ke Ji He, De Chen Wang, Xiao Qin Li, Li Xu

Gastroenterology Research · 2026-10 · 19 (5) · 295-301

DOI: 10.14740/gr2193 ↗

At a glance

Journal article in Gastroenterology Research, 2026-10. Written by Xin Shi and 5 co-authors. The full text is freely available (open access, CC BY-NC 4.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Cite

APA

Shi, X., Wang, W. J., He, K. J., Wang, D. C., Li, X. Q., & Xu, L. (2026). Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin. Gastroenterology Research, 19(5), 295-301. https://doi.org/10.14740/gr2193

Vancouver

Shi X, Wang WJ, He KJ, Wang DC, Li XQ, Xu L. Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin. Gastroenterology Research. 2026;19(5):295-301. doi:10.14740/gr2193

BibTeX
@article{Shi2026,
  author = {Shi, Xin and Wang, Wei Jun and He, Ke Ji and Wang, De Chen and Li, Xiao Qin and Xu, Li},
  title = {Pathological Complete Response in Stage IV Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer With Synchronous Liver Metastases After Conversion Therapy With SOX Plus Cadonilimab and Disitamab Vedotin},
  journal = {Gastroenterology Research},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {295--301},
  doi = {10.14740/gr2193}
}
Start for free →